Most of the information on BRCA1 and BRCA2 pathogenic mutations are tailored to women [74] due to the availability of effective surgical risk reduction procedures for breast and ovarian cancer among women [83–85]. This evidence concerns the gene BRCA2 and ovarian cancer.